• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mannatech Reports Financial Results for Third Quarter 2025

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025.

    Third Quarter Results

    • Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing demand in certain regions we operate within, however sales for the third quarter of 2025 were higher than the first two quarters of 2025.



    • Gross profit as a percentage of net sales increased to 76.4% for the three months ended September 30, 2025, as compared to 74.5% for the same period in 2024. The increase in gross profit as a percentage of net sales was primarily due to higher sales prices which was added in the third quarter of 2025 and lower inventory reserve additions compared to the same period in 2024. The timing of certain sales promotions also increased gross profit as a percentage of net sales during the quarter, compared to the same period in 2024.



    • Commission expenses for the three months ended September 30, 2025 decreased by 10.7%, or $1.3 million, to $10.9 million, as compared to $12.2 million for the same period in 2024. Commissions are earned from sales. Commission expenses in dollar terms decreased during the three months ended September 30, 2025 primarily due to a decline in our sales. For the three months ended September 30, 2025, commissions as a percentage of net sales decreased to 37.5% from 38.3% for the same period in 2024.



    • For the three months ended September 30, 2025, selling and administrative expenses decreased by $0.7 million, or 7.8%, to $9.1 million, as compared to $9.8 million for the same period in 2024. The decrease in selling and administrative expenses was the result of a $0.4 million reduction in payroll costs, a $0.1 million decrease in travel and entertainment costs, a $0.1 million decrease in warehouse costs and a $0.1 million decrease in charitable contributions. Selling and administrative expenses, as a percentage of net sales, for the three months ended September 30, 2025 increased to 31.1% from 31.0% for the same period in 2024.



    • Income from operations was $2.0 million for the three months ended September 30, 2025 as compared to $0.9 million in the same period last year.



    • Income tax expense was $0.6 million for the three months ended September 30, 2025 as compared to income tax benefit of  $0.4 million in the same period last year.



    • Net income was $1.9 million for the three months ended September 30, 2025, or $1.01 per diluted share, as compared to net loss of  $0.3 million, or $0.17 per diluted share for the three months ended September 30, 2024.



    • As of  September 30, 2025, the Company's cash and cash equivalents decreased 37.3%, or $4.3 million, to $7.1 million from $11.4 million as of December 31, 2024.



    • The approximate number of new and continuing independent associate and preferred customer positions held by individuals in Mannatech's network and associated with purchases of its products as of September 30, 2025 was approximately 119,000, as compared to 136,000 in the same period of 2024. Recruiting new associates and preferred customers decreased 21.9% in the third quarter of 2025 as compared to the third quarter of 2024.

    Management's Statement

    Changes in current trade policies, including with respect to tariffs, could affect our cost structure and profitability. While we take steps to mitigate or avoid these increased costs and disruptions, our ability to do so may be limited by operational and supply chain constraints and uncertainties, especially in the short term.

    Non-GAAP Financial Measures

    In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of Constant dollar measures. The company discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations.

    The Company believes that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors with an additional perspective on trends. Although management believes the non-GAAP financial measures enhance investors' understanding of their business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled "Non-GAAP Financial Measures" for a reconciliation of these non-GAAP financial measures.

    Safe Harbor statement

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "may," "will," "should," "hope," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "projects," "potential," and "continues" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

    ^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

    Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Mannatech.com.

    Contact Information:

    Erin K. Barta

    General Counsel and Corporate Secretary

    214-724-3378

    [email protected]

    www.mannatech.com 



    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS -(UNAUDITED)

    (in thousands, except share and per share information)

     
      
      September 30,

    2025
      December 31,

    2024
     
    ASSETS        
    Cash and cash equivalents $7,141  $11,396 
    Restricted cash  550   550 
    Accounts receivable, net of allowance of $783 and $935  38   19 
    Income tax receivable  732   737 
    Inventories, net  11,128   10,405 
    Prepaid expenses and other current assets  1,587   1,755 
    Deferred commissions  909   1,259 
    Total current assets  22,085   26,121 
    Property and equipment, net  3,232   2,858 
    Operating lease right-of-use assets  3,753   2,094 
    Other assets  2,828   2,644 
    Deferred tax assets, net  1,783   1,770 
    Long-term restricted cash  239   569 
    Total assets $33,920  $36,056 
    LIABILITIES AND SHAREHOLDERS' EQUITY        
    Commissions and incentives payable $6,407  $8,642 
    Accrued expenses  3,281   3,832 
    Deferred revenue  2,290   3,027 
    Accounts payable  4,005   2,070 
    Current portion of operating lease liabilities  1,745   1,178 
    Taxes payable  1,487   1,788 
    Current notes payable  —   84 
    Current portion of finance lease liabilities  288   275 
    Total current liabilities  19,503   20,896 
    Long-term notes payable  2,900   2,900 
    Operating lease liabilities, excluding current portion  2,702   1,576 
    Other long-term liabilities  1,402   1,390 
    Finance lease liabilities, excluding current portion  463   680 
    Total liabilities  26,970   27,442 
             
    Commitments and contingencies        
             
    Shareholders' equity:        
    Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding  —   — 
    Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,900,930 shares outstanding as of September 30, 2025 and 2,742,857 shares issued and 1,884,814 shares outstanding as of December 31, 2024  —   — 
    Additional paid-in capital  33,000   33,027 
    (Accumulated deficit) retained earnings  (2,729)  1,189 
    Accumulated other comprehensive loss  (3,759)  (5,666)
    Treasury stock, at average cost, 841,927 shares as of September 30, 2025 and 858,043 shares as of December 31, 2024  (19,562)  (19,936)
    Total shareholders' equity  6,950   8,614 
    Total liabilities and shareholders' equity $33,920  $36,056 



    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - (UNAUDITED)

    (in thousands, except per share information)
     
      
      Three Months Ended  Nine Months Ended 
      September 30,  September 30, 
      2025  2024  2025  2024 
    Net sales $29,161  $31,725  $81,403  $88,858 
    Cost of sales  6,890   8,105   20,495   20,763 
    Gross profit  22,271   23,620   60,908   68,095 
    Operating expenses:                
    Commissions and incentives  11,192   12,893   31,312   36,237 
    Selling and administrative expenses  9,072   9,840   29,865   31,293 
    Total operating expenses  20,264   22,733   61,177   67,530 
    Income (loss) from operations  2,007   887   (269)  565 
    Interest expense, net  (104)  (109)  (279)  (196)
    Other income (expense), net  611   (1,495)  (2,551)  495 
    Income (loss) before income taxes  2,514   (717)  (3,099)  864 
    Income tax (expense) benefit  (590)  389   (819)  (636)
    Net income (loss) $1,924  $(328) $(3,918) $228 
    Income (loss) per common share:                
    Basic $1.01  $(0.17) $(2.06) $0.12 
    Diluted $1.01  $(0.17) $(2.06) $0.12 
    Weighted-average common shares outstanding:                
    Basic  1,901   1,885   1,901   1,885 
    Diluted  1,901   1,885   1,901   1,885 



    Net sales by region for the three and nine months ended September 30, 2025 and 2024 were as follows (in millions, except percentages):

      Three Months Ended  Nine Months Ended 
      September 30,  September 30, 
    Region 2025  2024  2025  2024 
    Americas $7.9   27.1% $10.6   33.4% $25.1   30.8% $30.4   34.2%
    Asia/Pacific  18.8   64.4%  18.6   58.7%  49.5   60.8%  51.6   58.0%
    EMEA  2.5   8.5%  2.5   7.9%  6.8   8.4%  6.9   7.8%
    Total net sales $29.2   100.0% $31.7   100.0% $81.4   100.0% $88.9   100.0%



    Non-GAAP Financial Measures (Sales, Gross Profit and Income from Operations in Constant Dollars)

    To supplement its financial results presented in accordance with generally accepted accounting principles in the United States ("GAAP"), Mannatech discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. It refers to these adjusted financial measures as Constant dollar items, which are non-GAAP financial measures. The company believes these measures provide investors with an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, it calculates current year results and prior year results at a constant exchange rate, which is the prior year's rate. Currency impact is determined as the difference between the actual GAAP results and the recalculated results for the current year at the Constant dollar rates.

    The tables below reconcile third quarter 2025 and year-to-date Constant dollar net sales, gross profit and income from operations to GAAP net sales, gross profit and income from operations. (in millions, except percentages):

    Three-month period ended September 30, 2025  September 30, 2024  Constant $ Change 
      GAAP      Non-GAAP  GAAP         
      Measure:  Translation  Measure:  Measure:         
      Total $  Adjustment  Constant $  Total $  Dollar  Percent 
    Net sales $29.2  $0.2  $29.4  $31.7  $(2.3)  (7.3)%
    Gross profit $22.3  $0.1  $22.4  $23.6  $(1.2)  (5.1)%
    Loss from operations $2.0  $0.1  $2.1  $0.9  $1.2   133.3%

                                                                                                                                   

    Nine-month period ended September 30, 2025  September 30, 2024  Constant $ Change 
      GAAP      Non-GAAP  GAAP         
      Measure:  Translation  Measure:  Measure:         
      Total $  Adjustment  Constant $  Total $  Dollar  Percent 
    Net sales $81.4  $1.7  $83.1  $88.9  $(5.8)  (6.5)%
    Gross profit $60.9  $1.4  $62.3  $68.1  $(5.8)  (8.5)%
    Loss from operations $(0.3) $0.5  $0.2  $0.6  $(0.4)  (66.7)%





    Primary Logo

    Get the next $MTEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    9/10/24 5:45:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announces the promotion of Peter Griscom to Chief Operating Officer of Mannatech Incorporated (the "Company") effective July 1, 2025. Peter Griscom brings more than 10 years of experience in the direct selling channel and has extensive experience in working in the consumer goods space, including launching, leading, and restructuring companies while creating efficiencies in manufacturing, sales, and marketing. Prior to his promotion, Mr. Griscom served as the Company's senior vice president of global operations since August 21, 2024 and prior to that served as the senior vice president of product, innovation, & supply chain from July 3, 2023 through A

    6/26/25 2:11:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Chief Financial Officer Clavijo James

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:22:11 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 4 filed by General Counsel Barta Erin Kemmler

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:22:03 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form 4 filed by President and CEO Fredrick Landen Granvel

    4/A - MANNATECH INC (0001056358) (Issuer)

    8/28/25 4:21:55 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    SEC Filings

    View All

    Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    11/12/25 4:05:07 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Mannatech Incorporated

    10-Q - MANNATECH INC (0001056358) (Filer)

    11/12/25 4:03:53 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    9/12/25 4:22:20 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Financials

    Live finance-specific insights

    View All

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for First Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    5/13/25 6:06:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    View All

    Mannatech Announces Results of Annual Shareholders' Meeting

    Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

    6/5/25 2:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

    Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

    11/26/24 4:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

    7/1/24 5:46:00 PM ET
    $AEZS
    $MTEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Mannatech Incorporated

    SC 13G - MANNATECH INC (0001056358) (Subject)

    11/1/24 11:44:29 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    1/13/23 11:03:46 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    2/7/22 6:32:28 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care